Dexmedetomidine and Haloperidol for the management of emergence delirium in intensive care

Phase 3

• Conditions: Delirium in mechanically ventilated intensive care patients; Neurological - Other neurological disorders

• Registration Number: ACTRN12606000085572
• Lead Sponsor: Prince of Wales Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-03-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Patient requiring invasive ventilation for longer than 24 hours. 2. Receiving narcotics and /or sedatives for longer than 24 hours. 3. Development of clinical agitation and/or delirium upon weaning narcotics and/or sedatives on commencement of weaning from mechanical ventilation as per the POWSS. 4. Informed consent signed by person responsible within 24 hours of enrolment.

Exclusion Criteria

1. Allergy to any of the trial drugs.2. Patients who are or likely to be pregnant or lactating.3. Any patient with a Body Mass Index of >304. Patients receiving other long term alpha 2 agonists.5. Involvement in a sedation study within the last 30 days.6. Known opiate or benzodiazepines dependence, treatment for chronic pain or recent detoxification therapy within the last 6 months. 7. Patients on anti-psychotic drugs 8. Known dementia, Parkinsonism or epilepsy.9. Patients with recent cerebro-vascular surgery or traumatic brain injury.10. Any evidence of critical illness polyneuropathy.11. Patient with a recent tracheostomy.12. Recent surgery involving free flap.13. Haemodynamically unstable patients with Systolic blood pressure < 90 mmHg and or Heart rate < 55 / min.14. Patients on CVVHD.15. Patients with hepatic encephalopathy within 14 days.16. Patients with a recent drug overdose or CO poisoning.17. Patients who are Non-English Speaking background.

Study & Design

• Study Type: Interventional
• Study Design: Not specified